Expert Consulting and Modeling Services for Small Molecule Drug Design

Computational and AI Strategy

With over 30 years of pharma experience, CognitiX Medicine possessed a depth knowledge of a broad computational techniques for small molecule drug discovery. We specializes in assessing and evaluating computational technologies with a focus on their impacts in practices. We emphasize cognitive intelligence, fundamental science augmented by AI/ML techniques to thrive on human creativity in molecule design. We help our clients to develop strategies through internal and/or external investments to drive the medicinal chemistry and molecular design to a higher sophisticated level.

Medicine Design Consulating

Leverage the practical knowledge and proven impacts of computational techniques in drug candidate deliveries, CognitiX Medicine provides consultation on advanced and pragmatic techniques to optimize molecule design workflow, reduce Design-Make-Test cycle time, and maximize your return of investment.

Computational Modeling Service

With a track record of contributing to deliveries of clinical candidates for a broad range of targets in multiple disease areas, we provide computational modeling service to support your small molecule design and drug discovery effort. We could an integrated part of your embedded team in data analytics, modeling and hypothesis generations.

About CognitiX Medicine Consulting, LLC

CognitiX Medicine Consulting is founded by Dr. Xinjun Hou, a scientist with 30+ years of industrial experience in computational and AI-powered small molecule drug discovery.

In his last role as a senior scientific director at Pfizer, Dr. Xinjun Hou built a portfolio of computational innovations through internal Computational Chemistry Network Group and external partnerships. He spearheaded AI partnerships with PostEra, XtalPi, MIT, and University of Cambridge to build company's AI capabilities in molecular design, synthetic and computational chemistry. He developed strategic initiatives to strengthen core computational chemistry capabilities with XtalPi, Stanford University, and other partners such as OpenFF and OpenFE to advance in crystal structure prediction (CSP), molecular mechanics force field (XFF), molecular dynamics, and potency prediction techniques.

Dr. Xinjun Hou is a dedicated scientist committed to impact molecular design through computational modeling. He and his team of computational & cheminformatics scientists deployed SBDD, LBDD, Virtual Screening, QSAR, Generative Chemistry and AI/ML models to deliver more than 20 small molecule clinical candidates of in neuroscience, cardiovascular and metabolic, and antiviral disease areas.

Dr. Xinjun Hou started his career at Agouron Pharmaceutical Inc, a pioneer in structure-based drug design in San Diego, California, which was later acquired by Warner Lambert, then Pfizer. He was a cofounder of SABPA, SoCal Association for Biomedical and Pharmaceutical Advancements, a 501(c)(3) nonprofit organization launched in 2002 and now has over 4,000 members and subscribers, including scholars, professionals, and entrepreneurs within Southern California's biotech and pharmaceutical industries.